MMS22L and prostate adenocarcinoma: After integrating TMB data and MMS22L expression in pan-cancer, the TMB of 11 types of tumors (LUAD, COAD, READ, STES, KIPAN, STAD, prostate adenocarcinoma (PRAD), pheochromocytoma and paraganglioma (PCPG), ACC, and KICH) were positively related to MMS22L expression.